Research Article

Lignin-graft-PLGA drug-delivery system improves efficacy of MEK1/2 inhibitors in triple-negative breast cancer cell line

C Ethan Byrne

https://orcid.org/0000-0001-8722-0185

Department of Biological & Agricultural Engineering, Louisiana State University, LA 70803, USA

Search for more papers by this author

Carlos E Astete

Department of Biological & Agricultural Engineering, Louisiana State University, LA 70803, USA

Search for more papers by this author

Manibarathi Vaithiyanathan

Cain Department of Chemical Engineering, Louisiana State University, LA 70803, USA

Search for more papers by this author

Adam T Melvin

Cain Department of Chemical Engineering, Louisiana State University, LA 70803, USA

Search for more papers by this author

Mahsa Moradipour

Department of Chemical & Materials Engineering, University of Kentucky, KY 40506, USA

Search for more papers by this author

Stephen E Rankin

Department of Chemical & Materials Engineering, University of Kentucky, KY 40506, USA

Search for more papers by this author

Barbara L Knutson

Department of Chemical & Materials Engineering, University of Kentucky, KY 40506, USA

Search for more papers by this author

Cristina M Sabliov

Department of Biological & Agricultural Engineering, Louisiana State University, LA 70803, USA

Search for more papers by this author

Elizabeth C Martin

*Author for correspondence:

E-mail Address: emart93@lsu.edu

Department of Biological & Agricultural Engineering, Louisiana State University, LA 70803, USA

Search for more papers by this author

Published Online:2 Apr 2020https://doi.org/10.2217/nnm-2020-0010

View article

Abstract

Aim: Few targeted therapies are available for triple-negative breast cancer (TNBC) patients. Here, we propose a novel alkaline-lignin-conjugated-poly(lactic-co-glycolic acid) (L-PLGA) nanoparticle drug delivery system to improve the efficacy of targeted therapies. Materials & methods: L-PLGA nanoparticles (NPs) loaded with the MEK1/2 inhibitor GDC-0623 were characterized, tested in vitro on MDA-MB-231 TNBC cell line and compared with loaded PLGA NPs. Results: Loaded L-PLGA NPs were less than half the size of PLGA NPs, had slower drug release and improved the efficacy of GDC-0623 when tested in vitro. We demonstrated that GDC-0623 reversed epithelial-to-mesenchymal transition in TNBC. Conclusion: Our findings indicate that L-PLGA NPs are superior to PLGA NPs in delivering GDC-0623 to cancer cells for improved efficacy in vitro.

Graphical abstract

Keywords:

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

1. Breastcancer.org. Breast cancer information and support. www.breastcancer.org/ Google Scholar
2. Berry DA , Cirrincione C , Henderson IC et al. Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer. JAMA 295(14), 1658–1667 (2006). Crossref, Medline, CAS, Google Scholar
3. Higgins MJ , Baselga J . Targeted therapies for breast cancer. J. Clin. Invest. 121(10), 3797–3803 (2011). Crossref, Medline, CAS, Google Scholar
4. O’Rorke MA , Murray LJ , Brand JS , Bhoo-Pathy N . The value of adjuvant radiotherapy on survival and recurrence in triple-negative breast cancer: a systematic review and meta-analysis of 5507 patients. Cancer Treat. Rev. 47, 12–21 (2016). Crossref, Medline, Google Scholar
5. Hershman DL , Till C , Wright JD et al. Comorbidities and risk of chemotherapy-induced peripheral neuropathy among participants 65 years or older in Southwest Oncology Group clinical trials. J. Clin. Oncol. 34(25), 3014–3022 (2016). Crossref, Medline, CAS, Google Scholar
6. Chao C , Page JH , Yang SJ , Rodriguez R , Huynh J , Chia VM . History of chronic comorbidity and risk of chemotherapy-induced febrile neutropenia in cancer patients not receiving G-CSF prophylaxis. Ann. Oncol. 25(9), 1821–1829 (2014). Crossref, Medline, CAS, Google Scholar
7. Bradshaw PT , Stevens J , Khankari N , Teitelbaum SL , Neugut AI , Gammon MD . Cardiovascular disease mortality among breast cancer survivors. Epidemiology 27(1), 6–13 (2016). Crossref, Medline, Google Scholar
8. de Boer-Dennert M , de Wit R , Schmitz PI et al. Patient perceptions of the side-effects of chemotherapy: the influence of 5HT3 antagonists. Br. J. Cancer 76(8), 1055–1061 (1997). Crossref, Medline, CAS, Google Scholar
9. Tan KX , Danquah MK , Sidhu A , Ongkudon CM , Lau SY . Towards targeted cancer therapy: aptamer or oncolytic virus? Eur. J. Pharm. Sci. 96, 8–19 (2017). Crossref, Medline, CAS, Google Scholar
10. Zajac M , Muszalska I , Jelinska A . New molecular targets of anticancer therapy – current status and perspectives. Curr. Med. Chem. 23(37), 4176–4220 (2016). Crossref, Medline, CAS, Google Scholar
11. Oldham RK , Dillman RO . Monoclonal antibodies in cancer therapy: 25 years of progress. J. Clin. Oncol. 26(11), 1774–1777 (2008). Crossref, Medline, Google Scholar
12. Iannello A , Ahmad A . Role of antibody-dependent cell-mediated cytotoxicity in the efficacy of therapeutic anti-cancer monoclonal antibodies. Cancer Metastasis Rev. 24(4), 487–499 (2005). Crossref, Medline, CAS, Google Scholar
13. El-Khoueiry A , Kurkjian C , Semrad T et al. Abstract B75: a first in-human Phase I study to evaluate the MEK1/2 inhibitor GDC-0623 in patients with advanced solid tumors. Mol. Cancer Ther. 12(Suppl. 11), B75–B75 (2013). Crossref, Google Scholar
14. Heidorn SJ , Milagre C , Whittaker S et al. Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF. Cell 140(2), 209–221 (2010). Crossref, Medline, CAS, Google Scholar
15. Rajalingam K , Schreck R , Rapp UR Albert S . RAS oncogenes and their downstream targets. Biochim. Biophys. Acta 1773(8), 1177–1195 (2007). Crossref, Medline, CAS, Google Scholar
16. Bos JL . RAS oncogenes in human cancer: a review. Cancer Res. 49(17), 4682–4689 (1989). Medline, CAS, Google Scholar
17. Singh H , Longo DL , Chabner BA . Improving prospects for targeting RAS. J. Clin. Oncol. 33(31), 3650–3659 (2015). Crossref, Medline, CAS, Google Scholar
18. Sale MJ , Cook SJ . Intrinsic and acquired resistance to MEK1/2 inhibitors in cancer. Biochem. Soc. Trans. 42(4), 776–783 (2014). Crossref, Medline, CAS, Google Scholar
19. Adeyinka A , Nui Y , Cherlet T , Snell L , Watson PH , Murphy LC . Activated mitogen-activated protein kinase expression during human breast tumorigenesis and breast cancer progression. Clin. Cancer Res. 8(6), 1747–1753 (2002). Medline, CAS, Google Scholar
20. Thomas RS , Sarwar N , Phoenix F , Coombes RC , Ali S . Phosphorylation at serines 104 and 106 by Erk1/2 MAPK is important for estrogen receptor-alpha activity. J. Mol. Endocrinol. 40(4), 173–184 (2008). Crossref, Medline, CAS, Google Scholar
21. Kim R-K , Suh Y , Yoo K-C et al. Activation of KRAS promotes the mesenchymal features of basal-type breast cancer. Exp. Mol. Med. 47, e137 (2015). Crossref, Medline, Google Scholar
22. Hay M , Thomas DW , Craighead JL , Economides C , Rosenthal J . Clinical development success rates for investigational drugs. Nat. Biotechnol. 32(1), 40–51 (2014). Crossref, Medline, CAS, Google Scholar
23. Blagosklonny MV . Overcoming limitations of natural anticancer drugs by combining with artificial agents. Trends Pharmacol. Sci. 26(2), 77–81 (2005). Crossref, Medline, CAS, Google Scholar
24. Liu D , Auguste DT . Cancer targeted therapeutics: from molecules to drug delivery vehicles. J. Control. Rel. 219, 632–643 (2015). Crossref, Medline, CAS, Google Scholar
25. Suh MS , Shen J , Kuhn LT , Burgess DJ . Layer-by-layer nanoparticle platform for cancer active targeting. Int. J. Pharm. 517(1–2), 58–66 (2017). Crossref, Medline, CAS, Google Scholar
26. Gao J , Zhong W , He J et al. Tumor-targeted PE38KDEL delivery via PEGylated anti-HER2 immunoliposomes. Int. J. Pharm. 374(1–2), 145–152 (2009). Crossref, Medline, CAS, Google Scholar
27. Cerqueira BBS , Lasham A , Shelling AN , Al-Kassas R . Development of biodegradable PLGA nanoparticles surface engineered with hyaluronic acid for targeted delivery of paclitaxel to triple negative breast cancer cells. Mater. Sci. Eng. C Mater. Biol. Appl. 76, 593–600 (2017). Crossref, Medline, CAS, Google Scholar
28. Blanco E , Shen H , Ferrari M . Principles of nanoparticle design for overcoming biological barriers to drug delivery. Nat. Biotechnol. 33(9), 941–951 (2015). Crossref, Medline, CAS, Google Scholar
29. Danhier F , Feron O , Préat V . To exploit the tumor microenvironment: passive and active tumor targeting of nanocarriers for anti-cancer drug delivery. J. Control. Rel. 148(2), 135–146 (2010). Crossref, Medline, CAS, Google Scholar
30. Bae YH . Drug targeting and tumor heterogeneity. J. Control. Rel. 133(1), 2–3 (2009). Crossref, Medline, CAS, Google Scholar
31. Folkman J . Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat. Med. 1(1), 27–31 (1995). Crossref, Medline, CAS, Google Scholar
32. Matsumura Y , Maeda H . A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res. 46(12 Pt 1), 6387–6392 (1986). Medline, CAS, Google Scholar
33. Maeda H , Bharate GY , Daruwalla J . Polymeric drugs for efficient tumor-targeted drug delivery based on EPR-effect. Eur. J. Pharm. Biopharm. 71(3), 409–419 (2009). Crossref, Medline, CAS, Google Scholar
34. Sims LB , Curtis LT , Frieboes HB , Steinbach-Rankins JM . Enhanced uptake and transport of PLGA-modified nanoparticles in cervical cancer. J. Nanobiotechnol. 14, 33 (2016). Crossref, Medline, Google Scholar
35. Klapiszewski Ł , Zdarta J , Antecka K et al. Magnetite nanoparticles conjugated with lignin: a physicochemical and magnetic study. Appl. Surf. Sci. 422, 94–103 (2017). • Lignin conjugated to magnetite nanoparticles improved thermal and electrokinetic properties.Crossref, CAS, Google Scholar
36. Liu K , Zheng D , Lei H et al. Development of novel lignin-based targeted polymeric nanoparticle platform for efficient delivery of anticancer drugs. ACS Biomater. Sci. Eng. 4(5), 1730–1737 (2018). •• Alkaline lignin was conjugated to folic acid-polyethylene glycol to make a novel nanoparticle drug-delivery systems. The nanoparticle drug-delivery systems improved the efficacy of the targeted therapy hydroxyl camptothecin.Medline, CAS, Google Scholar
37. Wang X , Zhou X , Hecht SM . Role of the 20-hydroxyl group in camptothecin binding by the topoisomerase I-DNA binary complex. Biochemistry 38(14), 4374–4381 (1999). Crossref, Medline, CAS, Google Scholar
38. Muse ES , Patel NR , Astete CE , Damann KE , Sabliov CM . Surface association and uptake of poly(lactic-co-glycolic) acid nanoparticles by Aspergillus flavus . Ther. Deliv. 5(11), 1179–1190 (2014). Crossref, Medline, CAS, Google Scholar
39. Tabaei SR , Choi J-H , Haw Zan G , Zhdanov VP , Cho N-J . Solvent-assisted lipid bilayer formation on silicon dioxide and gold. Langmuir 30(34), 10363–10373 (2014). Crossref, Medline, CAS, Google Scholar
40. Cho N-J , Frank CW , Kasemo B , Höök F . Quartz crystal microbalance with dissipation monitoring of supported lipid bilayers on various substrates. Nat. Protoc. 5(6), 1096–1106 (2010). Crossref, Medline, CAS, Google Scholar
41. Patel AR , Frank CW . Quantitative analysis of tethered vesicle assemblies by quartz crystal microbalance with dissipation monitoring: binding dynamics and bound water content. Langmuir 22(18), 7587–7599 (2006). Crossref, Medline, CAS, Google Scholar
42. Evans K . Supported phospholipid bilayer interaction with components found in typical room-temperature ionic liquids – a QCM-D and AFM study. Int, J. Mol. Sci. 9(4), 498–511 (2008). Crossref, Medline, CAS, Google Scholar
43. Andersson M , Sellborn A , Fant C , Gretzer C , Elwing H . Acoustics of blood plasma on solid surfaces. J. Biomater. Sci. Polym. Ed. 13(8), 907–917 (2002). Crossref, Medline, CAS, Google Scholar
44. Santos-Martinez MJ , Inkielewicz-Stepniak I , Medina C et al. The use of quartz crystal microbalance with dissipation (QCM-D) for studying nanoparticle-induced platelet aggregation. Int. J. Nanomedicine 7, 243–255 (2012). Crossref, Medline, CAS, Google Scholar
45. Lind TK , Cárdenas M . Understanding the formation of supported lipid bilayers via vesicle fusion – a case that exemplifies the need for the complementary method approach (review). Biointerphases 11(2), 020801 (2016). Crossref, Medline, Google Scholar
46. Joshi T , Voo ZX , Graham B , Spiccia L , Martin LL . Real-time examination of aminoglycoside activity towards bacterial mimetic membranes using Quartz Crystal Microbalance with dissipation monitoring (QCM-D). Biochim. Biophys. Acta 1848(2), 385–391 (2015). Crossref, Medline, CAS, Google Scholar
47. Lesniak A , Salvati A , Santos-Martinez MJ , Radomski MW , Dawson KA , Åberg C . Nanoparticle adhesion to the cell membrane and its effect on nanoparticle uptake efficiency. J. Am. Chem. Soc. 135(4), 1438–1444 (2013). Crossref, Medline, CAS, Google Scholar
48. Shpigel N , Levi MD , Sigalov S , Daikhin L , Aurbach D . In situ real-time mechanical and morphological characterization of electrodes for electrochemical energy storage and conversion by electrochemical quartz crystal microbalance with dissipation monitoring . Acc. Chem. Res. 51(1), 69–79 (2018). Crossref, Medline, CAS, Google Scholar
49. Sadman K , Wiener CG , Weiss RA , White CC , Shull KR , Vogt BD . Quantitative rheometry of thin soft materials using the quartz crystal microbalance with dissipation. Anal. Chem. 90(6), 4079–4088 (2018). Crossref, Medline, CAS, Google Scholar
50. Chen KL , Bothun GD . Nanoparticles meet cell membranes: probing nonspecific interactions using model membranes. Environ. Sci. Technol. 48(2), 873–880 (2014). Crossref, Medline, CAS, Google Scholar
51. Yousefi N , Tufenkji N . Probing the Interaction between nanoparticles and lipid membranes by quartz crystal microbalance with dissipation monitoring. Front. Chem. 4, 46 (2016). Crossref, Medline, Google Scholar
52. Chen Q , Xu S , Liu Q , Masliyah J , Xu Z . QCM-D study of nanoparticle interactions. Adv. Colloid Interface Sci. 233, 94–114 (2016). Crossref, Medline, CAS, Google Scholar
53. Tong X , Moradipour M , Novak B et al. Experimental and molecular dynamics simulation study of the effects of lignin dimers on the gel-to-fluid phase transition in DPPC bilayers. J. Phys. Chem. B. 123(39), 8247–8260 (2019). Crossref, Medline, CAS, Google Scholar
54. Ábrahám Á , Katona M , Kasza G , Kiss É . Amphiphilic polymer layer – model cell membrane interaction studied by QCM and AFM. Eur. Polym. J. 93, 212–221 (2017). Crossref, CAS, Google Scholar
55. Frost R , Grandfils C , Cerda B , Kasemo B , Svedhem S . Structural rearrangements of polymeric insulin-loaded nanoparticles interacting with surface-supported model lipid membranes. J. Biomater. Nanobiotechnol. 2(2), 180–192 (2011). Crossref, Google Scholar
56. Zhao F , Holmberg JP , Abbas Z et al. TiO₂ nanoparticle interactions with supported lipid membranes – an example of removal of membrane patches. RSC Adv. 6(94), 91102–91110 (2016). Crossref, CAS, Google Scholar
57. Bailey CM , Kamaloo E , Waterman KL , Wang KF , Nagarajan R , Camesano TA . Size dependence of gold nanoparticle interactions with a supported lipid bilayer: a QCM-D study. Biophys. Chem. 203–204, 51–61 (2015). Crossref, Medline, CAS, Google Scholar
58. Jing B , Zhu Y . Disruption of supported lipid bilayers by semihydrophobic nanoparticles. J. Am. Chem. Soc. 133(28), 10983–10989 (2011). Crossref, Medline, CAS, Google Scholar
59. Reimhult K , Yoshimatsu K , Risveden K , Chen S , Ye L , Krozer A . Characterization of QCM sensor surfaces coated with molecularly imprinted nanoparticles. Biosens. Bioelectron. 23(12), 1908–1914 (2008). Crossref, Medline, CAS, Google Scholar
60. Tellechea E , Johannsmann D , Steinmetz NF , Richter RP , Reviakine I . Model-independent analysis of QCM data on colloidal particle adsorption. Langmuir 25(9), 5177–5184 (2009). Crossref, Medline, CAS, Google Scholar
61. Hasan IY , Mechler A . Formation of planar unilamellar phospholipid membranes on oxidized gold substrate. Biointerphases 11(3), 031017 (2016). Crossref, Medline, Google Scholar
62. Zwang TJ , Fletcher WR , Lane TJ , Johal MS . Quantification of the layer of hydration of a supported lipid bilayer. Langmuir 26(7), 4598–4601 (2010). Crossref, Medline, CAS, Google Scholar
63. Marquês JT , Viana AS , de Almeida RFM . A biomimetic platform to study the interactions of bioelectroactive molecules with lipid nanodomains. Langmuir 30(42), 12627–12637 (2014). Crossref, Medline, CAS, Google Scholar
64. Win KY , Feng S-S . Effects of particle size and surface coating on cellular uptake of polymeric nanoparticles for oral delivery of anticancer drugs. Biomaterials 26(15), 2713–2722 (2005). Crossref, Medline, CAS, Google Scholar
65. Qaddoumi MG , Ueda H , Yang J , Davda J , Labhasetwar V , Lee VHL . The characteristics and mechanisms of uptake of PLGA nanoparticles in rabbit conjunctival epithelial cell layers. Pharm. Res. 21(4), 641–648 (2004). Crossref, Medline, CAS, Google Scholar
66. Sahoo SK , Panyam J , Prabha S , Labhasetwar V . Residual polyvinyl alcohol associated with poly(D,L-lactide-co-glycolide) nanoparticles affects their physical properties and cellular uptake. J. Control. Rel. 82(1), 105–114 (2002). Crossref, Medline, CAS, Google Scholar
67. Uttamsingh S , Bao X , Nguyen KT et al. Synergistic effect between EGF and TGF-beta1 in inducing oncogenic properties of intestinal epithelial cells. Oncogene 27(18), 2626–2634 (2008). Crossref, Medline, CAS, Google Scholar
68. Gujral TS , Chan M , Peshkin L , Sorger PK , Kirschner MW , MacBeath G . A noncanonical Frizzled2 pathway regulates epithelial-mesenchymal transition and metastasis. Cell 159(4), 844–856 (2014). Crossref, Medline, CAS, Google Scholar
69. Casalino L , De Cesare D , Verde P . Accumulation of Fra-1 in RAS-transformed cells depends on both transcriptional autoregulation and MEK-dependent posttranslational stabilization. Mol. Cell. Biol. 23(12), 4401–4415 (2003). Crossref, Medline, CAS, Google Scholar
70. Astete CE , Sabliov CM . Synthesis and characterization of PLGA nanoparticles. J. Biomater. Sci. Polym. Ed. 17(3), 247–289 (2006). •• Presents a comprehensive review of poly(lactic-co-glycolic acid) (L-PLGA) nanoparticle (NP) synthesis methods and parameters that govern particle characteristics.Crossref, Medline, CAS, Google Scholar
71. Noguchi T , Yamamuro T , Oka M et al. Poly(vinyl alcohol) hydrogel as an artificial articular cartilage: evaluation of biocompatibility. J. Appl. Biomater. 2(2), 101–107 (1991). Crossref, Medline, CAS, Google Scholar
72. Xu A , Yao M , Xu G et al. A physical model for the size-dependent cellular uptake of nanoparticles modified with cationic surfactants. Int. J. Nanomedicine 7, 3547–3554 (2012). Medline, CAS, Google Scholar
73. Cartiera MS , Johnson KM , Rajendran V , Caplan MJ , Saltzman WM . The uptake and intracellular fate of PLGA nanoparticles in epithelial cells. Biomaterials 30(14), 2790–2798 (2009). •• Fluorescent PLGA NPs were used to explore cellular uptake and intracellular fate in three different epithelial cell lines.Crossref, Medline, CAS, Google Scholar
74. Bao W , Liu R , Wang Y et al. PLGA-PLL-PEG-Tf-based targeted nanoparticles drug delivery system enhance antitumor efficacy via intrinsic apoptosis pathway. Int. J. Nanomedicine 10, 557–566 (2015). • Modified PLGA NPs improved the efficacy of chemotherapy daunorubicin using in vivo xenograft models.Medline, Google Scholar
75. Davda J , Labhasetwar V . Characterization of nanoparticle uptake by endothelial cells. Int. J. Pharm. 233(1–2), 51–59 (2002). Crossref, Medline, CAS, Google Scholar
76. Kirtane AR , Kalscheuer SM , Panyam J . Exploiting nanotechnology to overcome tumor drug resistance: challenges and opportunities. Adv. Drug Deliv. Rev. 65(13–14), 1731–1747 (2013). Crossref, Medline, CAS, Google Scholar
77. Hatzivassiliou G , Haling JR , Chen H et al. Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers. Nature 501(7466), 232–236 (2013). • There are differences in constitutive MAPK pathway activation depending on whether it is KRAS or BRAF driven. These differences should be considered when designing drugs to target that pathway through MEK inhibition.Crossref, Medline, CAS, Google Scholar
78. Zaanan A , Okamoto K , Kawakami H , Khazaie K , Huang S , Sinicrope FA . The mutant KRAS gene up-regulates BCL-XL protein via STAT3 to confer apoptosis resistance that is reversed by BIM protein induction and BCL-XL antagonism. J. Biol. Chem. 290(39), 23838–23849 (2015). Crossref, Medline, CAS, Google Scholar
79. Shin S , Blenis J . ERK2/Fra1/ZEB pathway induces epithelial-to-mesenchymal transition. Cell Cycle 9(13), 2483–2484 (2010). Crossref, Medline, CAS, Google Scholar
80. Shin S , Dimitri CA , Yoon S-O , Dowdle W , Blenis J . ERK2 but not ERK1 induces epithelial-to-mesenchymal transformation via DEF motif-dependent signaling events. Mol. Cell. 38(1), 114–127 (2010). Crossref, Medline, CAS, Google Scholar
81. Khalil NM , do Nascimento TCF , Casa DM et al. Pharmacokinetics of curcumin-loaded PLGA and PLGA-PEG blend nanoparticles after oral administration in rats. Colloids Surf. B Biointerface. 101, 353–360 (2013). Crossref, Medline, CAS, Google Scholar
82. Xie X , Tao Q , Zou Y et al. PLGA nanoparticles improve the oral bioavailability of curcumin in rats: characterizations and mechanisms. J. Agric. Food Chem. 59(17), 9280–9289 (2011). Crossref, Medline, CAS, Google Scholar
83. Alexis F , Pridgen E , Molnar LK , Farokhzad OC . Factors affecting the clearance and biodistribution of polymeric nanoparticles. Mol. Pharm. 5(4), 505–515 (2008). Crossref, Medline, CAS, Google Scholar
84. Kumari A , Yadav SK , Yadav SC . Biodegradable polymeric nanoparticles based drug delivery systems. Colloids Surf. B Biointerfaces 75(1), 1–18 (2010). Crossref, Medline, CAS, Google Scholar
85. Masood F . Polymeric nanoparticles for targeted drug delivery system for cancer therapy. Mater. Sci. Eng. C Mater. Biol. Appl. 60, 569–578 (2016). Crossref, Medline, CAS, Google Scholar
86. Khalil NM , Carraro E , Cótica LF , Mainardes RM . Potential of polymeric nanoparticles in AIDS treatment and prevention. Expert Opin. Drug Deliv. 8(1), 95–112 (2011). Crossref, Medline, CAS, Google Scholar

Vol. 15, No. 10

Supplemental Materials

Metrics

Downloaded 181 times

History

Received 8 January 2020

Accepted 19 February 2020

Published online 2 April 2020

Published in print April 2020

Information

Keywords

Supplementary data

To view the supplementary data that accompany this paper please visit the journal website at: www.futuremedicine.com/doi/suppl/10.2217/nnm-2020-0010

Author contributions

The manuscript was written through contributions of all authors. All the authors have given approval to the final version of the manuscript.

Financial & competing interests disclosure

This work was supported by the National Science Foundation under NSF EPSCoR Track 2 RII, OIA 1632854; the USDA National Institute of Food and Agriculture, AFRI project #2017-07878; the USDA National Institute of Food and Agriculture, AFRI project #2018-07406; USDA-NIFA Hatch #1008750; and the National Science Foundation, CBET 1509713. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.

PDF download